Selected article for: "antiviral development and Ebola virus"
Author: Pagliano, Pasquale; Sellitto, Carmine; Scarpati, Giuliana; Ascione, Tiziana; Conti, Valeria; Franci, Gianluigi; Piazza, Ornella; Filippelli, Amelia
Title: An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19)
  • Cord-id: puyi2jp4
  • Document date: 2021_8_27
    • ID: puyi2jp4
    Snippet: INTRODUCTION: Remdesivir (RDV) is an inhibitor of the viral RNA-dependent RNA polymerases that are active in some RNA viruses, including the Ebola virus and zoonotic coronaviruses. When severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) was identified as the etiologic agent of the coronavirus disease 2019 (COVID-19), several investigations have assessed the potential activity of RDV in inhibiting viral replication, giving rise to hope for an effective treatment. AREAS COVERED: In this
    Document: INTRODUCTION: Remdesivir (RDV) is an inhibitor of the viral RNA-dependent RNA polymerases that are active in some RNA viruses, including the Ebola virus and zoonotic coronaviruses. When severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) was identified as the etiologic agent of the coronavirus disease 2019 (COVID-19), several investigations have assessed the potential activity of RDV in inhibiting viral replication, giving rise to hope for an effective treatment. AREAS COVERED: In this review, the authors describe the main investigations leading to the discovery of RDV and its subsequent development as an antiviral agent, focusing on the main clinical trials investigating its efficacy in terms of symptom resolution and mortality reduction. EXPERT OPINION: RDV is the most widely investigated antiviral drug for the treatment of COVID-19. This attention on RDV activity against SARS-CoV-2 is justified by promising in vitro studies, which demonstrated that RDV was able to suppress viral replication without significant toxicity. Such activity was confirmed by an investigation in an animal model and by the results of preliminary clinical investigations. Nevertheless, the efficacy of RDV in reducing mortality has not been clearly demonstrated.

    Search related documents:
    Co phrase search for related documents
    • action mechanism and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • action mechanism and liver express: 1
    • active metabolite and acute respiratory distress syndrome: 1, 2, 3
    • active metabolite and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • active triphosphate form and acute respiratory syndrome: 1, 2, 3, 4, 5
    • active triphosphate form and additional nucleotide: 1
    • active triphosphate metabolite and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7
    • activity demonstrate and acute respiratory distress syndrome: 1, 2, 3
    • activity demonstrate and acute respiratory distress syndrome evolve: 1
    • activity demonstrate and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory distress syndrome and administration timing: 1, 2, 3, 4
    • acute respiratory syndrome and additional nucleotide: 1
    • acute respiratory syndrome and administration timing: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15